CERo Therapeutics Company Insiders
| CEROW Stock | 0.01 0 14.29% |
CERo Therapeutics employs about 8 people. The company is managed by 8 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Recap of CERo Therapeutics' management performance can provide insight into the venture performance.
CERo |
CERo Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4528) % which means that it has lost $0.4528 on every $100 spent on assets. This is way below average. CERo Therapeutics' management efficiency ratios could be used to measure how well CERo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 0.0002 in 2024, whereas Return On Tangible Assets are likely to drop (0.0003) in 2024. At this time, CERo Therapeutics' Other Current Assets are fairly stable compared to the past year. Debt To Assets is likely to climb to 0.19 in 2024, whereas Total Assets are likely to drop slightly above 8.1 M in 2024.Common Stock Shares Outstanding is likely to climb to about 9.7 M in 2024
CERo Therapeutics Workforce Comparison
CERo Therapeutics Holdings is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 6,033. CERo Therapeutics adds roughly 8.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
CERo Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. CERo Therapeutics Price Series Summation is a cross summation of CERo Therapeutics price series and its benchmark/peer.
CERo Therapeutics Notable Stakeholders
A CERo Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CERo Therapeutics often face trade-offs trying to please all of them. CERo Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CERo Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Lawrence MD | Cofounder Board | Profile | |
| Christopher MBA | Interim Chairman | Profile | |
| Brian Atwood | President Director | Profile | |
| Charles Carter | Treasurer, CFO | Profile | |
| Kristen Pierce | Chief Director | Profile | |
| Robert MD | Consultant | Profile | |
| Daniel MD | Chief Officer | Profile | |
| Andrew MBA | Chief Officer | Profile |
About CERo Therapeutics Management Performance
The success or failure of an entity such as CERo Therapeutics often depends on how effective the management is. CERo Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CERo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CERo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.87) | (0.82) |
Please note, the imprecision that can be found in CERo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CERo Therapeutics Holdings. Check CERo Therapeutics' Beneish M Score to see the likelihood of CERo Therapeutics' management manipulating its earnings.
CERo Therapeutics Workforce Analysis
Traditionally, organizations such as CERo Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CERo Therapeutics within its industry.CERo Therapeutics Manpower Efficiency
Return on CERo Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 317 | |
| Net Loss Per Executive | 317 | |
| Working Capital Per Employee | 739K | |
| Working Capital Per Executive | 739K |
Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.